Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer - Contacts and Locations

Home

Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer

This study is ongoing, but not recruiting participants.

Study NCT00012376. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00012376

Locations


United States, Maryland
	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
	Baltimore, Maryland, United States, 21231

Sponsors and Collaborators

Sidney Kimmel Comprehensive Cancer Center

National Cancer Institute (NCI)

Investigators


Study Chair:	B. Douglas Smith, MD	Sidney Kimmel Comprehensive Cancer Center